OPRA Exam Flashcards

Q: How many questions are on the OPRA exam and how long do I have?

The OPRA exam has 120 multiple-choice questions completed in 150 minutes (2.5 hours). About 90% of questions are scored and 10% are unscored trial items spread across all five content areas, so there is no way to identify which questions do not count.

Q: What is the pass mark for OPRA?

The Australian Pharmacy Council does not publish a fixed percentage pass mark. OPRA uses a scaled (Rasch) standard-setting method, and candidates simply receive a result of pass or unsuccessful against the set competency standard.

Q: How many times can I retake the OPRA exam if I don't pass?

There is no official limit on attempts — the APC states you may resit as many times as you need to. However, the exam runs only in scheduled sittings (three times a year in 2026: March, July, and November), so failing means waiting for and re-registering for the next available sitting and paying the full fee again.

Q: Do I need employer sponsorship to sit the OPRA exam?

No. OPRA is a self-registered knowledge assessment — candidates register and pay directly through the APC candidate portal after completing an eligibility check. It is not tied to an employer or visa sponsor.

Q: Which content area should I prioritise most?

Therapeutics and Patient Care carries the heaviest weighting at 45% of the exam, covering PBS dispensing, medicine scheduling, counselling, harm minimisation and special populations — more than double any other single content area — so it deserves the largest share of study time.

Question 1

What is homeostasis, and why is it central to interpreting a patient's vital signs?

Accepted Answer

Homeostasis is the body's stable internal balance (temperature, pH, fluid/electrolyte levels). Vital sign changes usually signal a homeostatic mechanism struggling to compensate — recognising the disrupted parameter points to the underlying disease process.

Question 2

How does a negative feedback loop maintain homeostasis, and what happens when it fails?

Accepted Answer

A negative feedback loop senses a change from the set point and triggers a response that reverses it (e.g., rising blood glucose triggers insulin release to lower it). When the loop fails, the variable drifts uncontrolled — the basis of many chronic disease states.

Question 3

A patient has a suspected infection. What quick bedside criteria flag possible sepsis?

Accepted Answer

qSOFA (quick Sequential Organ Failure Assessment) and SIRS (Systemic Inflammatory Response Syndrome) are rapid screening tools using vitals (respiratory rate, blood pressure, mental status, temperature, heart rate) to flag patients at risk of sepsis needing urgent escalation.

Question 4

What three values does the body regulate to maintain acid-base balance, and why does this matter for drug therapy?

Accepted Answer

The body tightly controls blood pH, CO2 (respiratory component), and bicarbonate (metabolic component). Disturbances (acidosis/alkalosis) alter drug ionisation, renal excretion, and electrolyte handling, changing how some medicines behave.

Question 5

Which three electrolytes are most often disturbed by drug therapy, and why does this matter clinically?

Accepted Answer

Sodium, potassium, and calcium are the electrolytes most frequently disturbed by medicines (e.g., diuretics lowering potassium, ACE inhibitors raising it). Imbalances can cause arrhythmias, muscle weakness, or confusion, so monitoring is essential with high-risk drug classes.

Question 6

A lab report says a bacterium is 'Gram-positive.' What does this tell you, and how does it differ from Gram-negative?

Accepted Answer

Gram-positive bacteria have a thick peptidoglycan wall that retains crystal violet stain, appearing purple; Gram-negative bacteria have a thinner wall plus an outer membrane, staining pink. This distinction predicts likely antibiotic susceptibility and mechanism of action.

Question 7

How does innate immunity differ from adaptive immunity in speed and specificity?

Accepted Answer

Innate immunity is fast and non-specific (skin barrier, phagocytes, inflammation) and acts within minutes to hours. Adaptive immunity is slower to develop but specific and memory-based (T cells, B cells, antibodies), giving lasting protection after exposure or vaccination.

Question 8

Name three general mechanisms bacteria use to resist antibiotics.

Accepted Answer

Bacteria resist antibiotics by producing enzymes that inactivate the drug (e.g., beta-lactamase), pumping the drug out via efflux pumps, or altering the drug's target site so it no longer binds effectively.

Question 9

What are the four broad categories of vaccine, and how do they differ in what they deliver to the immune system?

Accepted Answer

Live attenuated (weakened whole organism), inactivated (killed organism), subunit (isolated antigen fragment), and mRNA (genetic instructions for the body to make the antigen itself) — each triggers an immune response by a different route, affecting durability and safety profile.

Question 10

Which three lab markers commonly indicate active inflammation or infection?

Accepted Answer

CRP (C-reactive protein), ESR (erythrocyte sedimentation rate), and WCC (white cell count) commonly rise with inflammation or infection. They support clinical judgement but are non-specific — none alone confirms a diagnosis.

Question 11

A drug is given orally instead of IV. What does 'bioavailability' measure about this difference?

Accepted Answer

Bioavailability is the fraction of an administered dose that reaches systemic circulation unchanged. IV doses have 100% bioavailability by definition; oral doses are usually lower due to incomplete absorption and first-pass metabolism.

Question 12

Why might an oral drug need a much higher dose than the same drug given IV?

Accepted Answer

Orally absorbed drugs pass through the portal vein to the liver before reaching systemic circulation — first-pass metabolism can inactivate a large fraction before it acts, so the oral dose must be higher to achieve the same effect.

Question 13

Why are some tablets enteric-coated, and what problem does this solve?

Accepted Answer

Enteric coating resists dissolution in stomach acid and only dissolves in the intestine's higher pH. It protects acid-labile drugs from destruction and/or protects the stomach lining from irritant drugs.

Question 14

How does a sustained-release formulation change a drug's dosing compared to an immediate-release version?

Accepted Answer

Sustained-release formulations slow drug release over time, producing steadier blood levels and allowing less frequent dosing — but they must not be crushed or split, as this can destroy the release mechanism and cause dangerous dose dumping.

Question 15

Name two factors affecting a drug's solubility, and why formulation stability matters for dispensing.

Accepted Answer

Solubility depends on factors like pH, particle size, and temperature. Stability describes a drug's resistance to degradation over time — poor stability can reduce potency or create toxic breakdown products, which is why storage conditions and expiry dates matter at dispensing.

Question 16

What does the ADME framework describe, and in what order do these processes typically occur?

Accepted Answer

ADME stands for Absorption, Distribution, Metabolism, and Excretion — the sequence a drug follows from entering the body, spreading through tissues, being chemically transformed (mainly by the liver), and finally being eliminated (mainly by the kidneys or bile).

Question 17

What does a drug's half-life tell you, and how many half-lives does it take to reach steady state?

Accepted Answer

Half-life is the time needed for a drug's plasma concentration to fall by half. It takes roughly 4-5 half-lives to reach steady state (and roughly the same to fully clear the drug), which is why loading doses are used for drugs with long half-lives.

Question 18

A drug has a very high volume of distribution. What does this suggest about where it is going in the body?

Accepted Answer

Volume of distribution (Vd) is an apparent value relating dose to plasma concentration. A high Vd suggests the drug is extensively distributed into tissues rather than staying in the blood, which matters for dosing and for dialysis removal in overdose.

Question 19

How does zero-order elimination differ from first-order elimination?

Accepted Answer

In first-order kinetics, a constant fraction of drug is eliminated per unit time (most drugs). In zero-order kinetics, a constant amount is eliminated regardless of concentration, because elimination pathways are saturated — small dose increases can cause disproportionate toxicity.

Question 20

What does a 'narrow therapeutic index' mean for how closely a drug needs to be monitored?

Accepted Answer

Therapeutic index compares the toxic dose to the effective dose. A narrow therapeutic index means the toxic and effective doses are close together, requiring close monitoring (e.g., levels, clinical signs) to avoid under- or over-dosing.

Question 21

A patient develops excessive bleeding on warfarin. Is this a Type A or Type B adverse drug reaction, and why?

Accepted Answer

This is a Type A ADR — predictable, dose-related, and an extension of the drug's known pharmacological effect. Type B ADRs are unpredictable and idiosyncratic (e.g., an allergic reaction), unrelated to dose.

Question 22

How does adding a CYP450 inhibitor to a patient's regimen differ in effect from adding a CYP450 inducer?

Accepted Answer

A CYP450 inhibitor slows metabolism of drugs sharing that pathway, raising their blood levels and toxicity risk. A CYP450 inducer speeds up metabolism, lowering levels and potentially causing therapeutic failure — the opposite clinical risk.

Question 23

Which combination of drug classes puts a patient at particular risk of serotonin syndrome?

Accepted Answer

Combining an SSRI (or other serotonergic drug) with an MAOI is a classic high-risk pairing for serotonin syndrome — a potentially life-threatening excess of serotonergic activity causing agitation, hyperthermia, and neuromuscular changes.

Question 24

Why do pharmacists screen for QT-prolonging drug combinations?

Accepted Answer

Multiple QT-prolonging drugs combined increase the risk of torsades de pointes, a dangerous ventricular arrhythmia. Screening for cumulative QT risk is a key medicines-safety check, especially in patients with other risk factors (electrolyte imbalance, cardiac disease).

Question 25

A patient presents with paracetamol overdose. What is the specific antidote?

Accepted Answer

N-acetylcysteine (NAC) is the antidote for paracetamol overdose — it replenishes glutathione stores to detoxify the toxic metabolite NAPQI before it causes hepatic damage.

Question 26

A patient shows respiratory depression from suspected opioid overdose. What antidote is given, and why must the patient still be monitored afterward?

Accepted Answer

Naloxone reverses opioid overdose by displacing opioids from receptors. Its effect can wear off before the opioid does (especially long-acting opioids), so ongoing monitoring and repeat dosing may be needed.

Question 27

Why is flumazenil rarely used to reverse benzodiazepine overdose despite being the specific antidote?

Accepted Answer

Flumazenil can precipitate seizures, particularly in patients who are benzodiazepine-dependent or who have co-ingested pro-convulsant drugs (e.g., tricyclic antidepressants), so its use is reserved for select, carefully monitored cases.

Question 28

Match the antidote to the poisoning: iron overdose, warfarin overdose, and organophosphate poisoning.

Accepted Answer

Iron overdose → desferrioxamine (chelates iron). Warfarin overdose/bleeding → vitamin K (restores clotting factor synthesis). Organophosphate/nerve agent poisoning → atropine (blocks excess cholinergic activity).

Question 29

What is the PBS, and what problem does it solve for patients?

Accepted Answer

The Pharmaceutical Benefits Scheme (PBS) subsidises the cost of listed prescription medicines in Australia, so patients pay only a co-payment rather than the full price — making essential medicines affordable and accessible.

Question 30

What is the difference between the general and concessional PBS co-payment amounts (2026)?

Accepted Answer

The general co-payment is up to AU$25 per script for patients without a concession card. The concessional co-payment is a lower fixed amount, AU$7.70 per script, for concession card holders — card status determines which fee applies.

Question 31

What happens once a patient's cumulative PBS spending crosses the Safety Net threshold?

Accepted Answer

Once a patient's PBS co-payments reach the annual Safety Net threshold (AU$1,748.20 general, AU$277.20 concessional in 2026), further PBS scripts become cheaper or free for the rest of the calendar year — concessional patients pay nothing further.

Question 32

A prescriber wants to prescribe a PBS medicine restricted beyond its standard listing. What must happen first?

Accepted Answer

An authority prescription is required — the prescriber must obtain PBS approval confirming the patient meets the restricted criteria before the medicine can be dispensed at the subsidised price.

Question 33

A patient's script says '5 repeats.' What does this allow, and what does it NOT allow?

Accepted Answer

Repeats let the patient receive further supplies of the same medicine without a new prescription, up to the authorised number and within the repeat's validity period. It does not allow dose changes or substitution of an unrelated medicine.

Question 34

A customer wants a Schedule 2 (S2) medicine. Can they select it from an open shelf without pharmacist involvement?

Accepted Answer

Yes — S2 (Pharmacy Medicine) can be self-selected by the customer, though it must be sold from a pharmacy and pharmacist advice must be available. S3 (Pharmacist Only) requires direct pharmacist involvement in the supply.

Question 35

What distinguishes a Schedule 4 (S4) medicine from S3, in terms of what's required before supply?

Accepted Answer

S4 (Prescription Only Medicine) requires a valid prescription from an authorised prescriber before it can be dispensed. S3 can be supplied by a pharmacist's own judgement without a script.

Question 36

Why do Schedule 8 (S8) medicines require extra record-keeping compared to S4 medicines?

Accepted Answer

S8 (Controlled Drug) medicines have recognised addiction/abuse/misuse potential (e.g., opioids, some stimulants), so they require additional legal controls — running balances, register entries, and often state-based authority for prolonged supply — beyond standard S4 requirements.

Question 37

What is a Schedule 9 (S9) substance, and how does it differ from S8?

Accepted Answer

S9 (Prohibited Substance) is banned from general sale, supply, and use except for limited research or government-approved purposes. Unlike S8 (available via legitimate prescription with controls), S9 has no accepted therapeutic supply pathway in ordinary practice.

Question 38

If a pharmacist is unsure which schedule a medicine belongs to, which document should they check?

Accepted Answer

The SUSMP (Standard for the Uniform Scheduling of Medicines and Poisons), also called the Poisons Standard, published by the TGA, is the authoritative reference for classifying every scheduled substance in Australia.

Question 39

What is AHPRA's core role in regulating Australian pharmacists?

Accepted Answer

AHPRA (Australian Health Practitioner Regulation Agency) administers national registration and handles notifications (complaints about conduct, health, or performance) across all regulated health professions, including pharmacy.

Question 40

If AHPRA handles registration administration, what does the Pharmacy Board of Australia do differently?

Accepted Answer

The Pharmacy Board of Australia sets the profession-specific practice standards, codes of conduct, and registration requirements for pharmacists, while AHPRA provides the shared administrative and regulatory operations across all health professions.

Question 41

What is the 'National Law' in the context of Australian health practitioner regulation?

Accepted Answer

The National Law is the legislation (Health Practitioner Regulation National Law) that establishes the National Registration and Accreditation Scheme, giving AHPRA and the National Boards (including the Pharmacy Board) their legal authority.

Question 42

A pharmacist becomes aware that a colleague is practising while significantly impaired by substance use. What legal obligation applies?

Accepted Answer

This triggers a mandatory notification obligation — registered health practitioners must report to AHPRA reasonable belief of impairment, intoxication while practising, significant departure from accepted standards, or sexual misconduct by a colleague, to protect the public.

Question 43

How does a provisionally registered (intern) pharmacist's practice differ from a fully registered pharmacist's?

Accepted Answer

Provisional registration is the intern pathway status for pharmacists completing their supervised training period before full registration — they must practise under supervision and cannot yet practise independently as a fully registered pharmacist.

Question 44

A patient asks for written information about a new medicine's side effects. What document should the pharmacist provide?

Accepted Answer

The CMI (Consumer Medicine Information) leaflet gives patient-friendly written information on a medicine's uses, dosing, precautions, and side effects, supplementing — not replacing — verbal pharmacist counselling.

Question 45

A community pharmacist identifies a patient on multiple medicines who may benefit from a structured review. What service applies?

Accepted Answer

MedsCheck is a community pharmacy medicine review service for patients with chronic conditions or multiple medicines, helping identify problems like interactions, adherence issues, or duplicate therapy directly within the pharmacy.

Question 46

How does an HMR differ from a MedsCheck in how it is initiated?

Accepted Answer

An HMR (Home Medicines Review) is GP-referred and typically conducted by an accredited pharmacist in the patient's home, focused on complex or high-risk medicine regimens — unlike MedsCheck, which is pharmacist-initiated within the pharmacy.

Question 47

An elderly patient struggles to keep track of multiple daily medicines. What packing service can help, and what is a key limitation?

Accepted Answer

A dose administration aid (DAA, e.g., Webster pack) organises doses by day and time to support adherence. A key limitation is that not all medicines are suitable for repacking (e.g., those affected by light, moisture, or requiring specific storage).

Question 48

Why must many drug doses be adjusted in a patient with reduced kidney function?

Accepted Answer

Reduced eGFR/creatinine clearance slows renal drug and metabolite elimination, raising the risk of accumulation and toxicity — doses of renally cleared drugs must be reduced or dosing intervals extended based on the patient's renal function.

Question 49

What is opioid substitution therapy, and name the two main medicines used.

Accepted Answer

Opioid substitution therapy uses long-acting opioid agonists — methadone (full agonist) or buprenorphine (partial agonist) — to stabilise patients with opioid dependence, reducing withdrawal, cravings, and harms associated with illicit opioid use.

Question 50

Which broad medicine categories are flagged as particularly high-risk in elderly patients, and why?

Accepted Answer

Anticholinergics and sedatives are flagged as high-risk in older patients because they increase confusion, falls risk, and injury — a key focus of medication reviews and deprescribing conversations in this population.

Free OPRA Exam Flashcards

Filter by Topic

Jump to Card

About These OPRA Flashcards

Topics Covered

Frequently Asked Questions

Overseas Pharmacist Readiness Assessment (OPRA)

Explore More Australia Pharmacy Exams

APC Intern Written Examination

Competency Assessment of Overseas Pharmacist (CAOP)